Home  /  Resource Library  /  Sustained Remissions after Discontinuation of Ibrutinib in Relapsed/Refractory CLL: A Basis for Reducing Drug Toxicity and Treatment Costs?

Sustained Remissions after Discontinuation of Ibrutinib in Relapsed/Refractory CLL: A Basis for Reducing Drug Toxicity and Treatment Costs?

These clinical observations suggest that interruption of ibrutinib may be feasible in at least some CLL patients who achieve remission.